Case Report

Pure posterior chordoid foramen magnum meningioma: A case report and review of literature

Ali Hammed a,⁎, Moufid Mahfoud a, Alaa Sulaiman a, Adnan Najm a, Salah Hammed b

a Tishreen University Hospital, Department of Neurosurgery, Lattakia, Syria
b Faculty of Medicine, Aleppo, Syria

ARTICLE INFO

Keywords:
Chordoid meningioma
Foramen magnum meningioma (FMM)
Pure posterior FMM

ABSTRACT

Introduction and importance: Meningiomas are extra-axial central nervous system (CNS) tumors that arise from the arachnoid cells of the dura mater [1]. Meningiomas represent 14.3–19% of all intracranial tumors, the most common non-glial primary intracranial tumor [1].

Only 1.8–3.2% of all meningiomas are located at foramen magnum (FM). Foramen magnum meningiomas (FMMs) represent a common histological tumor in a rare and eloquent location [1,2]. As these tumors are indolent, there occurs a long interval between onset of symptoms and diagnosis [2].

According to Boulton and Cusimano [3], Most lesions (68%–98%) arising anterolaterally, followed by postolateral, purely posterior and, more rarely, purely anterior [3].

In a review of Kepes et al., a relationship with Castleman syndrome was found, the features of which are delayed somatic and sexual development, hepatosplenomegaly, iron refractory hypochromic microcytic anemia, and bone marrow plasmacytosis with dysgamma-globulinemia [4–6]. This association was not found in the majority of other studies. In our case also, no systemic symptoms were present.

Chordoid meningioma is a rare subtype which is associated with a high likelihood of recurrence [7]. It represents only 0.5%–1% of all meningiomas and is grouped in WHO Grade II tumors [8]. They are mainly distributed in the supra-tentorial region [8]. Infra-tentorial chordoid meningioma is rare [7,8].

Our work is a single case report and has been reported in line with the SCARE criteria [21].

2. Case report

A 52-year-old female presented to our department of Neurosurgery (Lattakia, Syria) via community referral with the complaints of neck pain for 9 months in 2016, progressive weakness of all limbs in the form of rotating paralysis starting with weakness in triceps muscle in right upper limb followed by weakness in quadriceps muscle of the thigh in right lower limb, then weakness in quadriceps muscle of the thigh and biceps muscle in the left lower limb & left upper limb for 4 months with bowel bladder disturbance in the form of urgency & frequency. On
neurological examination patient was found to be quadri-paretic having muscle power Medical Research Council (MRC) grade 4 on right side & 3 on left side rendering her gait to be hemiplegic and walk with support. She also complained of hyperesthesia in the C2 dermatome (occipital region).

All her deep tendon reflexes were exaggerated with bilateral planter extensor.

She also complained of difficulty in swallowing and respiratory compromise.

There were no subcutaneous nodules, hypopigmented macules, or other stigmata of neurofibromatosis (NF). All other routine investigations were normal.

The patient’s review of systems and additional medical history surgical, family, psychosocial and pharmacologic were unremarkable.

Magnetic resonance imaging (MRI) T1 and T2 weighted image revealed well-defined dural-based mass lesion at foramen magnum, located posterior to neuroaxis. Post-contrast T1 weighted images revealed inhomogenously enhancing dural based lesion in the foramen magnum (Fig. 1).

After obtaining the patient’s informed consent, surgery was planned. The procedure was done by a consultant neurosurgeon with 17 years of experience.

The incision was extended through the deep layers and to the level of the suboccipital bone along the midline avascular fascial planes.

Blunt dissection was done to prevent injury to the vertebral artery.

C1 laminectomy was performed to allow for a wider dural opening and adequate lesional exposure.

The dura was opened in a Y-shaped fashion with a more inferior extension for more lateral mobilization of the dural flaps.

The tumor was encapsulated and well-defined. But it was very sticky to neurovascular components. It was also firmly attached to the dura. Due to the adhesions, a gross total resection was challenging to achieve. The tumor was first devascularized as much as is safely possible along its lateral attachments, and then centrally debulked. The vertebral arteries were dissected free and covered with a small cottonoid patty. Once the tumor was centrally debulked, its capsule was mobilized and all of the pial adhesions was sharply divided and small tumor feeders coagulated. Complete excision was done with coagulation of dural base.

The tumor was resected with preserving the neural and vascular structures. Simpson grade I was achieved.

Histopathology examination showed cords of eosinophil vacuolated cells in abundant myxoid matrix. The infiltration of lymphocytes or plasma cells was observed at the margin of the tumor.

Cells were immunopositive for epithelial membrane antigen (EMA) and vimentin. However, they were negative for glial fibrillary acidic protein (GFAP) and S100. Based on these findings, a diagnosis of choroid meningioma was rendered.

Post-operative MRI after 3 months shows no residual tumor (Fig. 2).

Patient is on close follow-up for the past 4 years and carrying out her routine life activities. Until now there has been no recurrence.

3. Discussion

The first case of meningioma arising at the foramen magnum was observed by Hallopeau at Lariboisiere Hospital in 1872 [9].

Foramen magnum meningioma is often identified only at an advanced stage due to the unusual and unrecognized pathognomonic symptomatology [10,11].

George et al. defined this area as a zone delimited anteriorly by the lower third of the clivus and upper edge of the body of axis (C2);

![Fig. 1. A: Post-contrast T1 weighted axial image, B: Post-contrast T1 weighted sagittal image: magnetic resonance imaging (MRI) showing pure posterior placed, inhomogenously enhancing dural based lesion measures 2 *2.5 CM in the foramen magnum (Blue arrow). C: T2 weighted axial image shows iso-tense lesion in the foramen magnum T1weighted sagittal image shows hypo-tense lesion in the foramen magnum. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)](image-url)
systemic symptoms were noted and none of the patient had lesion at FM. Symptoms varied from 3.5 months to 5 years (mean, 14.1 months). No systemic disease was there. None of the patients had a lesion at FM [7].

Infratentorial lesions have not been mentioned and none of the lesions are mentioned in FM location, we assume that no lesion was present in this region [17].

Differential diagnosis of tumor with chordoid/myxoid features includes chordoma, chordoid glioma, myxoid chondrosarcoma, myxopapillary ependymoma, and mucinous metastatic carcinoma. A panel of immunohistochemical markers is required to differentiate between these tumors. Chordomas are EMA/cytokeratin (CK)/S-100 positive. Chordoid gliomas are GFAP positive; chondrosarcomas stain positively with S-100 while chordoid meningioma is EMA positive. Myxopapillary ependymomas are exclusively located in conus medullaris, cauda equina, and fium terminale and are GFAP positive; metastatic carcinoma shows reactivity with CK [18].

Histologically, these tumors consisted of spindle or epithelial cells in a myxoid matrix. Two thirds of adult tumors showed mild-to-moderate inflammatory cells infiltration. It was infiltrated by many reactive lymphoplasmacytoid formation of follicles and germinal centers [7]. The infiltration of lymphocytes could be seen in our case, especially in the margin of the tumor, but without forming germinal centers. Immunohistochemical staining could be helpful for differential diagnosis. Chordoid meningioma is often immunoreactive by EMA, vimentin, PR, and D2-40, and occasionally positive by S-100 and cytokeratin, but consistently negative by GFAP [19]. Thus, a panel of antibodies comprising D2-40, EMA GFAP, and S-100 can distinguish CM from its histologic mimics as depicted in (Table 1).

In a study by Violaris et al., the majority (55.2%) of recurrences for Grade II meningioma was observed within 2 years from surgery and 94.7% within 5 years from surgery [20]. Fortunately, our patient shows no recurrence after 4 years of operation.

Surgical management of craniocervical junction meningiomas continues to present as a challenge to neurosurgeons especially in cases involving neighboring neurovascular structures.

The diagnosis of malignancy in patients with meningiomas has been a controversial issue. Only a histological study can confirm this situation. The association of pathological examination and immunohistochemical study can make a diagnosis of chordoid meningioma.

| Tumor                      | D2-40 | EMA | CK | GFAP | S-100 |
|----------------------------|-------|-----|----|------|-------|
| Chordoid meningioma        | +     | +   | ±  | −    | −     |
| Chordoid glioma            | +     | −   | +  | +    | +     |
| Chordoma                   | −     | +   | −  | +    | +     |
| Extraskeletal myxoid chondrosarcoma | −     | ±   | ±  | ±    | ±     |
| Skeletal myxoid chondrosarcoma | −     | −   | −  | +    | −     |
| Low-grade chondrosarcoma   | +     | −   | +  | −    | +     |
| Myxopapillary ependymoma   | −     | ±   | −  | −    | +     |
| Metastatic carcinoma       | −     | −   | +  | −    | −     |

EMA = Epithelial membrane antigen, CK= Cytokeratin, GFAP = Glial fibrillary acidic protein.
4. Conclusion

Although choroid meningioma is usually well circumscribed, sticky tumors should be suspected.

Complete resection without neurovascular injuries is the key for managing such lesions.

Recurrence of Chordoid meningioma should be suspected. Total excision should be achieved and routine follow-up should be informed.

Ethical approval

This study was not applicable for ethical approval.

Sources of funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author’s contribution

Dr. Ali Hammed (corresponding author): Contribution to the paper: first author, data collection, data analysis and interpretation, writing the paper.

Prof. Dr. Moufid Mahmoud: Contribution to the paper: Main Surgeon. Treatment and examination of the patient. Writing Case Presentation.

Dr. Salah Hammed: Contribution to the paper: Writing the paper.

Dr. Alaa Sulaiman: Contribution to the paper: Writing the paper.

Dr. Adnan Najm: Contribution to the paper: Writing the paper.

Registration of research studies

The case report at hand is not a first-in-man case report of a novel technology or surgical technique, therefore a registration of these case reports according to Declaration of Helsinki 2013 is not required.

Guarantor

Ali Hammed.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Declaration of competing interest

All authors declared no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2021.102325.

References

[1] N. Akalan, H. Seckin, C. Kılıç, T. Özgen, Benign extramedullary tumors in the foramen magnum region, Clin. Neurol. Neurosurg. 96 (4) (1994) 284–289.
[2] F.B. Meyer, M.J. Eberson, D.F. Reese, Benign tumors of the foramen magnum, J. Neurosurg. 61 (1) (1984) 136–142.
[3] M.R. Boulot, M.D. Cusimano, Foramen magnum meningiomas: concepts, classifications, and nuances, Neurorusc. Focus 14 (2003), e10.
[4] J.J. Kepes, W.Y. Chen, M.H. Connors, F.S. Vogel, “Chordoid” meningeval tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the castleman syndrome. A report of seven cases, Cancer 62 (1988) 391–406.
[5] H. Kobata, A. Kondo, K. Iwasa, H. Kunaka, H. Ito, S. Sawada, Chordoid meningioma in a child. Case report, J. Neurosurg. 88 (1998) 319–323.
[6] E. Salinero, L. Beltran, J.R. Costa, Intraoperative cytologic diagnosis of chordoid meningioma. A case report, Acta Cytol. 48 (2004) 259–263.
[7] M.E. Goux, F.V. Aker, B.W. Scheithauer, Chordoid meningioma: a clinicopathologic study of 42 cases, Am. J. Surg. Pathol. 24 (2000) 899–905.
[8] P. Kleihues, D.N. Louis, B.W. Scheithauer, L.R. Rorke, G. Reifenberger, P.C. Burger, W.K. Cavenee, The WHO classification of tumors of the nervous system, J. Neuropathol. Exp. Neurol. 61 (2002) 215–225.
[9] B. George, G. Lot, H. Boisnotten, Meningioma of the foramen magnum: a series of 40 cases, Surg. Neurol. 47 (1997) 371–379.
[10] B. Guidetti, A. Spallone, Benign extramedullary tumors of the foramen magnum, Surg. Neurol. 13 (9–17) (1986).
[11] S. Yasuoka, H. Okazaki, J. Daube, C.S. MacCarty, Foramen magnum tumors, J. Neurosurg. 49 (1978) 828–838.
[12] B. George, G. Lot, S. Vehat, F. Gelbert, K.L. Mourier, French language society of Neurorusc. 44th annual congress. Brussels, 8-12 June 1993. Tumors of the foramen magnum, Neurochirurgie 39 (Suppl 1) (1993) 1–89.
[13] J.J. Kepes, W.Y. Chen, M.H. Connors, F.S. Vogel, ‘Chordoid’ meningeval tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the castleman syndrome. A report of seven cases, Cancer 62 (1988) 391–406.
[14] A. Martí-Bracho, F. Rueda-Franco, A. Ibarra-de la Torre, O. García-González, L. Borstein-Quevedo, B. de León-Borjorge, Chordoid meningioma of the foramen magnum in a child: a case report and review of the literature, Child’s Nerv. Syst. 24 (3) (2008) 623–627.
[15] A. Kumar, S. Bhaskar, M. Bhardwaj, L.N. Gupta, Foramen magnum chordoid meningioma in a 22-Year-old female, Asian J. Neurosurg. 13 (3) (2018) 834–837.
[16] M.L. Yang-Suck, M.A. Collado-Ortìz, C. Salinas-Lara, R. García-Gonz, D. Rembaó-Bojórquez, Chordoid meningioma: a report of ten cases, J. Neuro Oncol. 99 (2010) 41–48.
[17] Y. Yang, D. Li, X.Y. Cao, S.Y. Hao, L. Wang, Z. Wu, et al., Clinical features, treatment, and prognostic factors of chordoid meningioma: radiological and pathological features in 60 cases of chordoid meningioma, World Neurosurg. 93 (2016) 198–207.
[18] S. Siraj, M.K. Ansari, K.C. Sharma, A. Singh, Chordoid meningioma:A diagnostic dilemma, J. Canc. Res. Therapeut. 11 (2015) 663.
[19] S. Mori, K. Oka, H. Hakozaki, et al., Chordoid meningioma. A case report, Pathol. Res. Pract. 197 (2001) 515–518.
[20] K. Violari, V. Katsarides, P. Sakellariou, The recurrence rate in meningiomas: analysis of tumor location, histological grading, and extent of resection, Int. J. Mol. Neurorsurg. 2 (2012) 6–10.
[21] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, A. Kerwan, A. Thoma, A.J. Beamish, A. Noureddin, A. Rao, B. Vasudevan, B. Challacombe, B. Perakath, B. KinULSEIN, B. Ekser, C.S. Pramesh, D.M. Laskin, D. Machado-Aranda, D. Miguel, D. Pagano, F. H. Millham, G. Roy, H. Kadioglu, J.L. Nixon, I. Mukhejee, J.A. McCaul, J. Chi-Yong Ng, J. Albrecht, J.G. Rivas, K. Raveendran, L. Derbyshire, M.H. Ather, M. A. Thorat, M. Valmasoni, M. Bashashati, M. Chalkoo, N.Z. Teo, N. Raison, O. J. Muensterer, P.J. Bradley, P. Goel, P.S. Rai, R.Y. Afifi, R.D. Rosin, R. Coppola, R. Klappenbach, R. Wynn, R.L. De Wilde, S. Surani, S. Giordano, S. Massarut, S. G. Raja, S. Basu, S.A. Enam, T.G. Manning, T. Cross, V.K. Karanth, V. Kastisvananathan, Z. Mei, The SCARE 2020 guideline: updating consensus surgical Case REport (SCARE) guidelines, Int. J. Surg. (2020), https://doi.org/10.1016/j.ijscr.2020.10.034.